The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.

På svenska

Author

Summary, in English

The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.

Department/s

  • Breastcancer-genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2011

Language

English

Pages

1097-1107

Publication/Series

Glycobiology

Volume

21

Issue

8

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Biochemistry and Molecular Biology

Keywords

  • monoclonal antibody
  • in vivo therapy
  • antigen
  • Tn
  • anti-carbohydrate
  • biomarker

Status

Published

ISBN/ISSN/Other

  • ISSN: 1460-2423